DOCSLIB.ORG

(19) United States (12) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(19) United States (12) Patent Application Publication (10) Pub US 20130035391A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0035391 A1 Katayama et al. (43) Pub. Date: Feb. 7, 2013 (54) FELBINAC-CONTAINING TRANSDERMALLY Publication Classi?cation ABSORBABLE PREPARATION (51) Int. Cl. (75) Inventors: Akiko Katayama, HigashikagaWa-shi A61K31/192 (200601) (JP); Katsuyuki [1100’ (52) US. Cl. ..................................................... .. 514/570 HigashikagaWa-shi (JP) (57) ABSTRACT (73) Assignee: TEIKOKU SEIYAKU CO., LTD., An adhesive patch is a felbinac-containing transdermally KanagaWa (JP) absorbable preparation substantially free of a solubiliZer for felbinac in a ?nal preparation but still having high releasing of (21) Appl. NO.I 13/516,008 felbinac. The adhesive patch in Which lidocaine and felbinac are formulated has the releasing of felbinac Without losing the (22) PCT Filed: Dec- 14: 2010 releasing of lidocaine. The felbinac-containing transderrnally absorbable adhesive patch contains felbinac as an active com (86) PCT N05 PCT/JP2010/072453 ponent and lidocaine or a pharmaceutically acceptable salt § 371 (OX1), thereof as an absorption promoter. In particular, the content of (2)’ (4) Date; Aug 16, 2012 felbinac is from 0.1% to 10% by Weight to the total Weight of the drug-containing plaster and the content of lidocaine or the (30) Foreign Application Priority Data pharmaceutically acceptable salt thereof is from 0.01% to 20% by Weight to the total Weight of the drug-containing Dec. 15, 2009 (JP) ............................... .. 2009-284325 plaster. Patent Application Publication Feb. 7, 2013 Sheet 1 0f 3 US 2013/0035391 A1 [FIG. 1] FELB l NAG PERMEAB | L l TY 41. 000 8 12 086%%0 TIME (hr) —x— COMPARATIVE EXAMPLE 1 EXAMPLE 1 L | DOOAI NE PERMEABI LITY m0 33 0 m 2 5 O 2. U D 235E555M222855%15 11 505 00“U0 TIME-‘(1.10 I ‘*"FGOMPARATIVE EXAMPLE 2! + EXAMPLE 1 Patent Application Publication Feb. 7, 2013 Sheet 2 0f 3 US 2013/0035391 A1 LFIIIG. ‘ s1 KETOPROFEN PERMEABILITY ' 100 600. D .U TIME (hr) ‘ l —-‘+— COMPARATIVE EXAMPLE 3] +GQMPARAT|VE EXAMPLE 4 I [FIG. 4], LIDQCALNE PERMEABILITY" ' TIME (hrY -' K- COMPARATIVE EXAMPLE 2% —-—.i:—-COMPARATIVE EXAMPLE 4_‘ Patent Application Publication Feb. 7, 2013 Sheet 3 0f 3 US 2013/0035391 A1 [FIG. 5], INDOMETHACIN PERMEABI LlTY L 5U @65353%‘@?EmEM5525 TIME (hr) ~2M-0OMPARATIME EXAMPLE 5 COMPARATIVE EXAMPLE 6 [FIG. 6]‘ LIDOCAINE PERMEAB] LITY \nn a.“ ___L LIMA A_ TM w.@m%5 4W U8O \wi. TIME Khl’)‘ -><- COMPARATIVE EXAMPLE 21+,c0MPARAnvE EXAMPLE 6! US 2013/0035391A1 Feb. 7, 2013 FELBINAC-CONTAINING TRANSDERMALLY patch, these formed salts and inhibited the drug releasing of ABSORBABLE PREPARATION each other, thereby failing to obtain a desired medicinal effect. TECHNICAL FIELD PRIOR ART DOCUMENTS [0001] The present invention relates to a transdermally absorbable preparation, and more particularly, to an adhesive Patent Documents patch containing felbinac, a non-steroidal anti-in?ammatory analgesic, as a medicinal component and lidocaine or a phar [0009] Patent Document 1: Japanese Patent Application maceutically acceptable salt thereof being a local anesthetic Laid-Open No. Hei. 4-321624 and as an absorption promoter to felbinac. [0010] Patent Document 2: Japanese Patent Application Laid-Open No. 2001-342130 BACKGROUND ART [0011] Patent Document 3: Japanese Patent Application [0002] Felbinac, Which is a non-steroidal anti-in?amma Laid-Open No. 2003-286162 tory analgesic, is an active metabolite of fenbufen and a drug [0012] Patent Document 4: Japanese Patent Application having high anti-in?ammatory and analgesic activity. Felbi Laid-Open No. 2002-128699 nac has been transdermally administered to avoid systemic [0013] Patent Document 5: International Publication No. side effects and available as external preparations such as a WO 01/047559 gel, a liquid, a cataplasm, and a plaster. [0014] Patent Document 6: Japanese Patent Application [0003] Felbinac itself has very loW solubility in various Laid-Open No. 2005-145931 solvents. Thus, a variety of solubiliZers have been conven [0015] Patent Document 7: Japanese Patent Application tionally used in such external preparations to enhance the Laid-Open No. 2005-145932 transdermal absorption of felbinac. [0016] Thus, as for the adhesive patch in Which a non [0004] For example, Patent Document 1 has proposed a steroidal anti-in?ammatory analgesic and a local anesthetic felbinac -containing plaster Which contains crotamiton having as a transdermal absorption promoter are formulated, it has high solubiliZing ability for felbinac as an essential compo been desired to develop the transdermally absorbable prepa nent. Also, Patent Document 2 has proposed a plaster in ration Which achieves high anti-in?ammatory and analgesic Which N-methyl-2-pyrrolidone and polyethylene glycol are effects Without inhibiting drug releasing of each other. formulated as the solubiliZers. Many of such solubiliZers, hoWever, have caused irritation to the skin. Moreover, When [0017] Under such circumstances, as for felbinac among such liquid components are formulated in an adhesive patch, non-steroidal anti-in?ammatory analgesics, the present a change of the physical properties of the adhesive patch may inventors have intensively studied development of the trans be caused over time by the bleed-out to the surface (the dermally absorbable preparation, Which achieves high anti exudation to the surface) of the adhesive patch. in?ammatory and analgesic effects Without inhibiting the drug releasing of each other, by formulating felbinac With a [0005] In addition, Patent Document 3 has proposed a plas local anesthetic as a transdermal absorption promoter. ter free of crotamiton and containing a styrene-isoprene-sty rene block copolymer, a rosin resin, a plasticiZer, l-menthol, [0018] As a result, When lidocaine Was selected as the and felbinac. This plaster is an adhesive patch in Which fel absorption promoter and formulated together With the non binac is uniformly dispersed in a semi-molten state in the steroidal anti-in?ammatory analgesic felbinac in an adhesive adhesive layer, i.e., in a state Wherein felbinac is present in a patch base, it Was found that a uniform drug-containing plas molten state and in a ?ne crystalline state simultaneously. The ter Was obtained even substantially free of the solubiliZer for drug permeability hoWever Was not suf?cient because part of felbinac to provide a felbinac-containing transdermally felbinac Was present in a crystalline state. absorbable preparation having high releasing of main drugs While the transdermally absorbable preparation had excellent [0006] Further, a combination preparation in Which a non analgesic and anti-in?ammatory activity Without losing the steroidal anti-in?ammatory analgesic and a local anesthetic transdermal absorption of lidocaine as the local anesthetic, are formulated has been studied Wherein the preparation has thereby completing the present invention. both an anti-in?ammatory activity of the non-steroidal anti in?ammatory analgesic and an analgesic activity of the local SUMMARY OF THE INVENTION anesthetic. [0007] For example, Patent Document 4 and Patent Docu Problems to be Solved by the Invention ment 5 have proposed a cataplasm in Which a non-steroidal anti-in?ammatory analgesic such as indomethacin, felbinac, [0019] Thus, it is a ?rst object of the present invention to diclofenac sodium and loxoprofen sodium and a local anes provide a felbinac-containing transdermally absorbable thetic such as lidocaine, benZocaine and dibucaine are formu preparation substantially free of a solubiliZer for felbinac in a lated. Also, Patent Document 6 and Patent Document 7 have ?nal preparation but still having high releasing of felbinac to proposed a tape in Which a non-steroidal anti-in?ammatory solve the above-mentioned conventional problems. analgesic and a local anesthetic are formulated respectively. [0020] Further, it is a second object of the present invention [0008] In general, hoWever, many local anesthetics are to provide an adhesive patch in Which a local anesthetic and basic drugs, While many non-steroidal anti-in?ammatory felbinac, Which is the non-steroidal anti-in?ammatory anal analgesics to be formulated together are acidic drugs includ gesic, are formulated, Wherein the adhesive patch has excel ing indomethacin and ketoprofen. Accordingly, When these lent releasing of the non-steroidal anti-in?ammatory analge both drugs Were simultaneously formulated in the adhesive sic Without losing the releasing of the local anesthetic. US 2013/0035391A1 Feb. 7, 2013 Means for Solving the Problem [0033] FIG. 6 is a graph shoWing the result of in vitro rat skin permeability test for lidocaine based on Comparative [0021] A basic aspect of the present invention to solve such Study (3) of Test Example 1. problems is a felbinac-containing transdermally absorbable adhesive patch, Which contains felbinac as an active compo EMBODIMENTS FOR CARRYING OUT THE nent and lidocaine or a pharmaceutically acceptable salt INVENTION thereof as an absorption promoter. [0022] Speci?cally, the present invention is the felbinac [0034] The basic aspect of the present invention, as containing transdermally ab sorbable adhesive patch Wherein described above, is the felbinac-containing transdermally the content of felbinac is from 0.1% to 10% by Weight to the absorbable adhesive patch, Which contains felbinac as an total Weight of the drug-containing plaster base material and anti-in?ammatory analgesic medicinal component and the content of lidocaine or the pharmaceutically acceptable lidocaine or a pharmaceutically acceptable salt thereof as an salt thereof is from 0.01% to 20% by Weight to the total absorption promoter. Weight of the drug-containing plaster base material. [0035] The formulated amount of the active component [0023] Especially, the present invention is the felbinac-con felbinac in the adhesive patch of the present invention is from taining transdermally absorbable adhesive patch Wherein an 0.1% to 10% by Weight and particularly preferably from 0.2% adhesive patch base is a rubber polymer and the rubber poly to 5% by Weight to the total Weight of the drug-containing mer is a styrene-isoprene-styrene block copolymer.
Load more

Recommended publications
  • Scottish Medicines Consortium
    Scottish Medicines Consortium diclofenac 1% gel patches (Voltarol Gel PatchÒ) No. (199/05) Novartis 9 September 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission Diclofenac 1% gel patch (Voltarol Gel PatchÒ) is not recommended for use within NHS Scotland for the local symptomatic treatment of pain in epicondylitis and ankle sprain. Diclofenac gel patch provides analgesia similar to that obtained with a topical gel formulation of this drug. However, on a gram per gram basis, patches cost over 40% more than the gel formulation. Overleaf is the detailed advice on this product. Chairman, Scottish Medicines Consortium 1 Diclofenac 1% gel patch (Voltarol Gel Patch®) Licensed indication under review Local symptomatic treatment of pain in epicondylitis and ankle sprain in adults. Dosing information under review Epicondylitis: one application morning and night for up to fourteen days. Ankle sprain: one application per day for up to three days. UK launch date 1 October 2005 Comparator medications Conditions included in the indications of diclofenac 1% gel patch, epicondylitis (tennis elbow) and ankle sprain could be treated topically with gel formulations of other non-steroidal anti- inflammatory drugs (NSAIDs), including diclofenac, ibuprofen, piroxicam, ketoprofen and felbinac or systemically with oral formulations of these drugs
    [Show full text]
  • Diclofenac Topical Patch Gel Solution Monograph
    Diclofenac Topical Patch, Gel and Solution National Drug Monograph March 2016 VHA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Action Diclofenac is the only nonsteroidal antiinflammatory drug (NSAID) approved in the U.S. for topical application. The mechanism of diclofenac is believed to be inhibition of prostaglandin synthesis, primarily by nonselectively inhibiting cyclooxygenase. The agents covered in this review are the four diclofenac topical products approved for analgesic purposes: Diclofenac epolamine / hydroxyethylpyrrolidine patch (DEHP) 1.3% approved in January 2007 Diclofenac sodium topical gel 1%, approved in October 2007 Diclofenac sodium topical solution 1.5% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in November 2009 Diclofenac sodium topical solution 2% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in January 2014 Indication(s) Under Review in this document (may include off Solution 1.5% Solution 2% label) Patch 1.3% Gel 1% (Drops) (MDP) Topical treatment Relief of the pain of Treatment of signs Treatment of the Also see Table 1 Product Descriptions of acute pain due osteoarthritis of joints and symptoms of pain of below. to minor strains, amenable to topical osteoarthritis of the osteoarthritis of sprains, and treatment, such as the knee(s) the knee(s) contusions knees and those of the hands.
    [Show full text]
  • Ketoprofen 2.5% Gel: a Clinical Overview
    European Review for Medical and Pharmacological Sciences 2011; 15: 943-949 Ketoprofen 2.5% gel: a clinical overview S. COACCIOLI Rheumatology Unit, Santa Maria General Hospital, Terni (Italy) Abstract. – Ketoprofen (KP), a non- therefore, with fewer serious adverse events steroidal anti-inflammatory drug (NSAID), pos- (AEs)2. Current guidelines produced by the Euro- sesses analgesic, antipyretic and anti-inflamma- pean League Against Rheumatism (EULAR) and tory properties. Oral KP is widely used in mus- culoskeletal pain and inflammation in muscles the Osteoarthritis Research Society International and joints, including arthritis pain, osteoarthritis, (OARSI) suggest that topical NSAIDs are pre- stiffness of the joints, soft tissue rheumatism, ferred over oral NSAIDs for patients with mild to and sports injuries. In common with all NSAIDs, moderate knee or hand OA with few affected oral KP has been associated with systemic ad- joints, and/or a history of sensitivity to oral verse events and in particular gastrointestinal NSAIDs3,4. The favourable benefit/risk ratio of disorders. Topical application of the active ingre- dient is locally effective and at the same time topical NSAIDs has been further confirmed by a minimises the risk of systemic adverse events. recent Cochrane meta-analysis of 47 randomized Pharmacokinetic studies show that serum levels studies5. Because there are a number of topical of the active ingredient following topical KP formulations of NSAIDs currently available, 2.5% gel are less than 1% of those reported after there is a need to summarize the evidence sup- oral dosing, thereby providing good levels of porting the effectiveness and safety of each for- pain relief without the systemic adverse events mulation.
    [Show full text]
  • Analgesic Efficacy and Safety of Transdermal and Oral Diclofenac in Postoperative Pain Management Following Dental Implant Placement
    Analgesic efficacy and safety of transdermal and oral diclofenac in postoperative pain management following dental implant placement Raja Rajeswari S., MDS ¢ Triveni M. Gowda, MDS ¢ Tarun A.B. Kumar, MDS ¢ Dhoom S. Mehta, MDS Kanchan Arya, MDS The aim of this study was to compare the efficacy and ehabilitation of partially and completely edentulous safety of transdermal and oral routes of diclofenac for areas with dental implants is well established, with postoperative pain management in patients undergo- numerous advantages over conventional procedures. ing dental implant placement. Twenty systemically R A recent meta-analysis demonstrated a 95.2% survival rate and healthy, partially edentulous patients who required 84.9% success rate in single-crown–supported implants, signi- 1 dental implants bilaterally in the mandibular first molar fying the predictability of this treatment modality. The pain region were included. While the patient was under local following implant surgery is categorized generally as mild to anesthesia, an implant was placed in the mandibular moderate and generally is at its maximum level 5-6 hours post- 2 first molar region of one quadrant. After a minimum postoperatively. If appropriate surgical guidelines—including of 4 weeks, an implant was placed in the contralateral precise incision, gentle tissue handling, heat control with quadrant under local anesthesia. Patients were pre- copious irrigation during osteotomy preparation, intermittent scribed 50 mg of oral diclofenac, taken twice daily for 3 drilling pressure, and end-to-end closure of sutures—are fol- days, following implant placement on the first side and lowed prudently, postoperative pain can be mitigated consider- a 100-mg diclofenac transdermal patch, placed once ably.
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • Innovations from 'Down-Under': a Focus on Prescription to Non-Prescription Medicine Reclassification in New Zealand and Australia
    ORIGINAL ARTICLE SelfCare 2012;3(5):88-107 Advancing the study&understanding of self-care INNOVATIONS FROM ‘DOWN-UNDER’: A FOCUS ON PRESCRIPTION TO NON-PRESCRIPTION MEDICINE RECLASSIFICATION IN NEW ZEALAND AND AUSTRALIA NATALIE GAULD*, FIONA KELLY**, LYNNE EMMERTON†, LINDA BRYANT††, STEPHEN BUETOW‡ * PhD Candidate, Department of General Practice and Primary Health Care, University of Auckland, New Zealand **Honorary Senior Lecturer, School of Pharmacy, University of Auckland, New Zealand †Associate Professor, School of Pharmacy, Curtin Health Innovation Research Institute, Perth, Western Australia †† Honorary Lecturer, Department of General Practice and Primary Health Care, University of Auckland, New Zealand ‡Associate Professor, Department of General Practice and Primary Health Care, University of Auckland, New Zealand ABSTRACT BACKGROUND: Australia and New Zealand (NZ) contribute to the international trend of medicines reclassification from prescription to non-prescription availability (switch). Both countries have been acknowledged as being as advanced or even more so than the United Kingdom (UK) in availability of medicines without prescription, despite not making some of the recent innovative UK switches. OBJECTIVE: To derive a measure of progressiveness in switch; to compare the progressiveness of switch between NZ and Australia; and to compare NZ and Australia switch activity with the UK. METHODS: Records of medicines classification meetings in Australia and NZ from 2000 to 2011 were analysed with respect to all switch considerations (whether approved or not approved). Switches in Australia and NZ were compared with those in the UK. A new measure, ‘innovative switches’, was developed to provide a useful measure of switch progress. RESULTS: Australia demonstrated ‘switch innovation’ in the early 2000s, including the ‘first-in-world’ switch of orlistat, but has slowed down since.
    [Show full text]
  • A Thesis Entitled Design, Optimization and Evaluation of a Novel Emulgel
    A Thesis entitled Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen for Enhanced Skin Delivery using Formulating for Efficacy™ software by Aastha Chadha Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences Industrial Pharmacy ________________________________________ Gabriella Baki, Ph.D., Committee Chair ________________________________________ Caren L. Steinmiller, Ph.D., Committee Member ________________________________________ Jerry Nesamony, Ph.D., Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo May, 2018 Copyright 2018, Aastha Chadha This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen using Formulating for Efficacy™ Software by Aastha Chadha Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences Industrial Pharmacy The University of Toledo May 2018 Development of novel formulations present unique challenges in selecting the optimum formulation type for a given active ingredient. The topical route has long been used for delivering drugs directly to the affected target site through the skin. Current approaches in design and optimization of topical formulations necessitate extensive decisions in choosing the right components for the formulation to achieve high safety, clinical efficacy, and patient compliance. It is a resource-intensive process, which involves a certain degree of hit-and-trial on the part of the formulator. Solubility of the active ingredient in the vehicle and the skin is an important parameter in selecting and optimizing vehicle components for topical formulation development.
    [Show full text]
  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T (51) International Patent Classification: (74) Common Representative: UNIVERSITY OF VETER¬ A61K 9/06 (2006.01) A61K 47/32 (2006.01) INARY AND PHARMACEUTICAL SCIENCES A61K 9/14 (2006.01) A61K 47/38 (2006.01) BRNO FACULTY OF PHARMACY; University of A61K 47/10 (2006.01) A61K 9/00 (2006.01) Veterinary and Pharmaceutical Sciences Brno Faculty Of A61K 47/18 (2006.01) Pharmacy, Palackeho 1/3, CZ-61242 Brno (CZ). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CZ20 12/000073 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 August 2012 (02.08.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, 201 1-495 11 August 201 1 ( 11.08.201 1) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 2012- 72 1 February 2012 (01.02.2012) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2012-5 11 26 July 2012 (26.07.2012) ZW.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0004305 A1 Miura Et Al
    US 201200.04305A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0004305 A1 Miura et al. (43) Pub. Date: Jan. 5, 2012 (54) EXTERNAL PREPARATION CONTAINING Publication Classification ANALGESCAANTI-NFLAMMATORY AGENT (51) Int. Cl. A6II 3/196 (2006.01) (75) Inventors: Seiji Miura, Shizuoka (JP): A6IP 29/00 (2006.01) Makoto Kanebako, Shizuoka (JP) A6II 47/44 (2006.01) A6II 47/08 (2006.01) (73) Assignee: Kowa Co., Ltd., Nagoya-shi (JP) A6II 47/10 (2006.01) (52) U.S. Cl. ......................................... 514/567; 514/772 (21) Appl. No.: 13/256,024 (57) ABSTRACT (22) PCT Fled: Mar. 11, 2010 An external preparation containing the following compo nents (A), (B), (C), and (D): (86) PCT NO.: PCT/P10/01760 (A) a non-steroidal analgesic/anti-inflammatory agent, (B) a terpene and/or an essential oil containing a terpene, S371 (c)(1), (C) a higher alcohol, and (2), (4) Date: Sep. 12, 2011 (D) a polyoxyalkylene alkyl ether and/or a polyoxyalky lene alkenyl ether. The external preparation of the (30) Foreign Application Priority Data present invention has improved skin permeation, and can thus be effective at a low concentration, and also has Mar. 11, 2009 (JP) ................................. 2009-057972 excellent appearance. US 2012/0004305 A1 Jan. 5, 2012 EXTERNAL PREPARATION CONTAINING external application containing alkyl pyrrolidone, hydro ANALGESCAANTI-NFLAMMATORY AGENT philic polyether, hydrophilic nonionic Surfactants, water soluble polymer Substances having a carboxyl group, water TECHNICAL FIELD soluble vinyl polymers, water-insoluble multivalent metal salts, polyhydric alcohol, organic hydroxy acid, and water 0001. The present invention relates to an external prepa (see Patent Document 6), a piroXicam-containing transder ration containing a non-steroidal analgesic/anti-inflamma mal system containing, as an adhesive, a copolymer com tory agent.
    [Show full text]
  • Topical Nsaids for Chronic Musculoskeletal Pain in Adults (Review)
    Cochrane Database of Systematic Reviews Topical NSAIDs for chronic musculoskeletal pain in adults (Review) Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD007400. DOI: 10.1002/14651858.CD007400.pub3. www.cochranelibrary.com Topical NSAIDs for chronic musculoskeletal pain in adults (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 10 Figure1. ..................................... 11 Figure2. ..................................... 14 Figure3. ..................................... 16 Figure4. ..................................... 17 Figure5. ..................................... 20 DISCUSSION ..................................... 22 Figure6. ..................................... 23 AUTHORS’CONCLUSIONS . 24 ACKNOWLEDGEMENTS . 25 REFERENCES ..................................... 26 CHARACTERISTICSOFSTUDIES . 31 DATAANDANALYSES. 73 Analysis 1.1. Comparison 1 Topical diclofenac versus carrier, Outcome 1 Clinical success. 74 Analysis
    [Show full text]